2024 ASCO-GU前列腺癌精粹解读——从常规手段到立体定向,放疗技术在前列腺癌的更新与推进  

The interpretation and review of prostate cancer,2024 ASCO-GU--from conventional fractionation to stereotactic body radiation therapy,the update of radiation technology in the treatment of prostate cancer

作　　者：刘洋 何立儒[1] Liu Yang;He Liru(Department of Radiation Oncology,State Key Laboratory of Oncology in South China,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]华南恶性肿瘤防治全国重点实验室、广东省恶性肿瘤临床医学研究中心、中山大学肿瘤防治中心放疗科,广州510060

出　　处：《中华泌尿外科杂志》2024年第4期258-260,共3页Chinese Journal of Urology

摘　　要：2024年美国临床肿瘤学会泌尿生殖肿瘤年会(ASCO-CU)报道了局限期前列腺癌领域有关剂量提升、疗程缩短等根治性放疗的优化、术后短疗程放疗的挑战,以及放疗技术的迭代等多方面研究进展。本文对其中重要研究进行解读和点评,以期为全面认识放疗技术的发展,尤其是立体定向放射治疗(SBRT)在局限期前列腺癌中的应用提供帮助。The 2024 American Society of Clinical Oncology Genitourinary(ASCO-GU)Cancers Symposium presented the latest research advancements in dose escalation and hypofractionation of radical radiotherapy(RT),the challenges associated with post-operative hypofractionated or ultrahypofractionated RT,and the technical developments in RT for prostate cancer.This article aims to interpret and review these significant studies,providing a comprehensive understanding of RT technical advancements,particularly focusing on the application of stereotactic body radiation therapy(SBRT)in localized prostate cancer.

关 键 词：前列腺癌 研究进展 立体定向放射治疗 

分 类 号：R737.25[医药卫生—肿瘤]